TD Asset Management’s BridgeBio Pharma BBIO Stock Holding History

TD Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.41M	Sell	59,246 -77,256	-57%	-$5.41M	﹤0.01%	829
2026 Q1	$10.1M	Sell	136,502 -7,678	-5%	-$557K	0.01%	638
2025 Q4	$11M	Buy	144,180 +55,230	+62%	+$3.63M	0.01%	633
2025 Q3	$4.62M	Buy	+88,950	New	+$4.34M	﹤0.01%	800
2024 Q2	–	Sell	-29,074	Closed	-$899K	–	1370
2024 Q1	$899K	Hold	29,074	–	–	﹤0.01%	1184
2023 Q4	$1.17M	Buy	+29,074	New	+$873K	﹤0.01%	1146
2021 Q3	–	Sell	-23,432	Closed	-$1.25M	–	1529
2021 Q2	$1.25M	Sell	23,432 -12,837	-35%	-$733K	﹤0.01%	1211
2021 Q1	$2.23M	Buy	+36,269	New	+$2.37M	﹤0.01%	1081

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

TD Asset Management's BBIO Position: Q2 2026 in Review

TD Asset Management reduced its BridgeBio Pharma (BBIO) stake by 57% in Q2 2026, selling an estimated $5.41M and leaving 59,246 shares worth $4.41M. The position accounts for ﹤0.01% of the portfolio, ranked #829.

TD Asset Management first reported a position in BBIO in Q1 2021 and has held it in 8 quarters since. The position peaked at $11M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

TD Asset Management held 59,246 shares of BridgeBio Pharma worth $4.41M as of Q2 2026.
TD Asset Management sold 77,256 BridgeBio Pharma shares in Q2 2026, an estimated $5.41M.
BridgeBio Pharma made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #829 holding.
TD Asset Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 8 quarters since.
TD Asset Management's BridgeBio Pharma position peaked at $11M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.